Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of TD-4208 in Moderate Hepatic Impairment
NCT02581592Phase 1Completed
- Sponsor
- Mylan
- Start
- Nov 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of revefenacin in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Mylan. Primary endpoint: Maximum Observed Plasma Concentration. Started Nov 2015; status: completed.
02
Drugs
revefenacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02581592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581592.